An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, August 2008

Altmetric Badge

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 53 Mendeley

Summary Policy documents Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model

Article in Neuropsychiatric Disease and Treatment (June 2022)

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

Article in Neuropsychiatric Disease and Treatment (January 2021)

Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia

Article in Srpski Arhiv Za Celokupno Lekarstvo (January 2019)